Abstract
Inflammation severity predicts mortality risk in intensive care unit (ICU) patients. Hyperphenylalaninemia (HPA) is associated with inflammation. We investigated whether a phenylalanine (PHE)-free diet (PFD) reduces PHE, downstream metabolite, and proinflammatory cytokine levels in patients with HPA. This study enrolled ICU patients with PHE levels of ≥95 μM. They were divided into PFD and usual diet (UD) groups. Changes in PHE, downstream metabolite, and proinflammatory cytokine levels were assessed over a 5-day period. We included 66 propensity score–matched patients (PFD: 33; UD: 33). Reductions in PHE levels were greater in the PFD group (from 136 ± 44.7 to 97.0 ± 41.7 μM) than in the UD group (from 125 ± 24.5 to 108 ± 30.9 μM; p = 0.008). PFD group exhibited greater reductions in phenylpyruvate, hydroxyl-phenyllactate, interleukin-6, interleukin-10, tumor necrosis factor-α, and macrophage inflammatory protein-1β levels and a smaller increase in interferon-inducible T-cell α chemoattractant level than did the UD group (all p<0.05). Lower PHE intake was associated with lower cytokine levels. PFD intake was associated with a trend of lowering 15-day mortality (p = 0.072). Our findings suggest that PFD intake reduces the levels of PHE and proinflammatory cytokines in ICU patients with HPA. Randomized placebo-controlled trials are required to elucidate the benefits of PFDs.
Keywords: phenylalanine, metabolite, dietary intervention, intensive care unit
Introduction
Despite substantial advances in therapeutic modalities and strategies, mortality rates among critically ill patients admitted to intensive care units (ICUs) remain high.(1,2) Thus, identification of new therapeutic targets is urgently required. Phenylalanine (PHE), an essential amino acid, is a key component of the human body. Blood concentrations of PHE are usually tightly controlled at a steady state, and deviations in these concentrations (i.e., high or low blood PHE levels) are associated with poor health.(3–6) Hyperphenylalaninemia (HPA), or high blood PHE levels, can occur in adults with or without congenital phenylketonuria (PKU). When the body encounters severe oxidative stress or inflammation, PHE cannot be adequately converted into tyrosine, resulting in excessive accumulation of PHE and its downstream metabolites.(7) Inflammation severity can predict mortality risk in the ICU.(8) Accumulated evidence suggests that HPA is associated with an increased mortality rate in patients with advanced cardiovascular diseases, heart failure,(3–5) infection,(9) COVID-19,(10,11) or critical illnesses requiring ICU admission.(5,12) However, whether HPA can serve as a therapeutic target remains unknown.
PKU is a congenital metabolic disorder caused by a defect in the PHE hydroxylase (PAH) gene.(13) The considerably high plasma level of PHE (>600 μM) in newborns with PKU leads to increased oxidative stress and has been associated with severe brain damage and even early mortality.(14) Early diagnosis and immediate adherence to a PHE-restricted diet with PHE-free protein supplementation may prevent severe brain damage in individuals with PKU.(14) In adults without PKU, plasma PHE concentrations normally range from 48.7 to 85.4 μM.(12) Notably, among adult patients with sepsis or those receiving ICU care, mild to moderate elevations in plasma PHE levels (i.e., levels exceeding the normal range and up to 600 μM) have been strongly associated with an increased risk of mortality.(5,9,12)
The mechanism underlying poor HPA outcomes in adults without PKU differs from that underlying PKU.(3,5,9,12) Although an elevated plasma PHE level may be a byproduct of inflammatory stress and tissue breakdown in patients in the ICU, mounting evidence supports the direct toxic effects of PHE on vital organs in adults with normal PAH.(4,15–19) Furthermore, phenylpyruvate, the first downstream metabolite of PHE in the catabolic pathway, induces excessive NLRP3 inflammasome activation and pathological inflammation.(20) Whether dietary restriction of PHE effectively reduces phenylpyruvate levels and downstream inflammatory metabolites, thereby improving inflammation in critically ill patients, remains unknown.
Critical care nutrition guidelines typically recommend high-protein supplementation during critical illness to facilitate tissue repair. However, diets high in protein also contain high amounts of PHE. For patients with abnormal PHE metabolism, high-protein supplementation increases the risk of HPA. Currently, the standard method for reducing plasma PHE levels (to protect the brain) in patients with PKU is to administer a PHE-free diet (PFD) that is rich in PHE-free protein and antioxidant micronutrients.(13,14,21) Whether PFDs can also confer acute-phase benefits in ICU patients with HPA but without PKU remains unclear. The present study investigated whether short-term use of a PFD can reduce the plasma levels of PHE, downstream toxic metabolites, and proinflammatory cytokines in ICU patients with HPA. On the basis of previous studies,(5,12) patients with a baseline plasma PHE level of ≥95 μM had a lower rate of 90-day survival than did those with a baseline plasma PHE level of <95 μM. Thus, a plasma PHE level of 95 μM was selected as the threshold for the initiation of a PFD. The findings may inform the clinical application of PFDs.
Materials and Methods
Study cohort and data collection
From January 2020 to December 2022, we consecutively enrolled eligible patients with cardiovascular diseases receiving ICU care. Patients were included if they had an Acute Physiology and Chronic Health Evaluation II score of ≥15, were intubated for respiratory failure, were receiving enteral feeding through a nasogastric feeding tube, and were aged >20 years. Patients were excluded if they had terminal stage cancer likely to compromise survival beyond 3 months, had COVID-19, were undergoing hemodialysis, were fasting, were receiving partial or total parenteral nutrition, or were expected to stay in the ICU for <5 days (Fig. 1). Written informed consent was obtained from patients or next of kin (approval number: 201801514B0, 202000831B0, and 202100028A3; ClinicalTrials.gov ID: NCT04896281).
Fig. 1.

Flow diagram of the study. NG, nasogastric; PHE, phenylalanine.
Baseline fasting plasma PHE levels were measured in the morning of the day after ICU admission (Day 1; Fig. 1 and Supplemental Fig. 1*). Patients were enrolled if they had a fasting plasma PHE level of ≥95 μM. Demographic and laboratory data were collected at ICU admission and in the morning of Day 1.
Study design
This study had a nonequivalent pretest–posttest control group design. Patients were allocated to a PFD group or a usual diet (UD) group on the basis of whether they agreed to receive a PFD (Fig. 1). We investigated PFD-induced changes in the plasma levels of PHE, PHE-derived downstream metabolites, and proinflammatory cytokines over a 5-day period. Metabolites and cytokines were analyzed only in patients who completed the PFD intervention. To fairly compare the changes in plasma PHE level between the UD and PFD groups, propensity score matching was conducted; this helped us adjust for the effects of potential confounders. We also assessed mortality over a 15-day period.
Intervention
Relevant diet was administered through a nasogastric feeding tube from the night after the measurement of PHE level. The PFD group received a PFD (diet components are presented in Supplemental Table 1*), whereas the UD group received standard nutritional formulas that met individual needs. We tried to reach the nutrition goals within the first week of ICU admission: reach >80% of the calorie (25–30 kcal/kg/day; 11–14 kcal/current body weight/day in cases of obesity) and the recommended protein intake (1.2–2.0 g/kg/day, depending on the patient’s liver and kidney function). Continuous feeding according to digestion status was provided for patients with poor digestion. Enteral nutrition was initiated at an original rate of 20 ml/h and adjusted by 5–10 ml/h every 12 h according to patient tolerance, gradually titrating toward the target goal.
In the PFD group, once the plasma PHE level was ≥95 μM (reported at 5 PM on Day 1), the PFD (Phenex-2; Abbott Nutrition, Columbus, OH) was started as the only nutrition source for enteral feeding, as per the recommendation of dieticians, and maintained until the morning of Day 5 (Details of the PFD intervention are provided in Supplemental Fig. 1*). The PHE-free formula was reconstituted according to the manufacturer’s instructions to achieve a caloric density of 1 kcal/ml. For comparison, the components of a PHE-free milk diet and other usual enteral feeding diets are listed in Supplemental Table 1*. In the UD group, an individualized diet was administered as prescribed by dieticians on the basis of established guidelines.(22,23) Dietary intake for each group was calculated as the average daily amount consumed between plasma PHE measurements on Days 1 and 5. Furthermore, 24-h calorie, protein, and PHE intakes on Day 1 and Day 4 (final day) were analyzed to assess changes in these components across the intervention period.
Blood sampling and examination
Fasting blood samples were collected in EDTA-containing tubes at approximately 5 AM on Day 1. Plasma levels of PHE, tyrosine, plasma p-cresyl sulfate, PHE-derived downstream metabolites, and cytokines were then measured. Other parameters such as albumin, estimated glomerular filtration rate, C-reactive protein, and hemoglobin were measured in the central laboratory.
Measurement of proinflammatory cytokines
A Milliplex MAP Human High Sensitivity T Cell Magnetic Bead Panel (MILLIPLEX HSTCMAG-28SK Kit; Millipore, Burlington, MA) was used to quantify plasma cytokine levels. Antibody beads, controls, wash buffer, serum matrix, and standards were prepared following the manufacturer’s instructions. Next, plates were analyzed using a MAGPIX system with the xPONENT software. Measured cytokines included granulocyte-macrophage colony-stimulating factor, interferon, interferon-inducible T-cell α chemoattractant (ITAC), macrophage inflammatory protein, tumor necrosis factor, fractalkine, and various interleukins (ILs).
Measurement of plasma PHE and tyrosine
Once collected, blood samples were immediately sent to the laboratory for the measurement of plasma levels of PHE and tyrosine, which were quantified using ultraperformance liquid chromatography (UPLC). Plasma samples (100 μl) were precipitated with 10% sulfosalicylic acid. After protein precipitation and centrifugation, derivatization was initiated using aminoquinolyl-carbamyl in acetonitrile. Amino acids were then analyzed using an ACQUITY UPLC system (Waters, Milford, MA), which consisted of a binary solvent manager, a sample manager, and a tunable ultraviolet detector. The EmpowerTM 2 software was used to control the system and collect data. Separations were performed on a 2.1 mm × 100 mm ACQUITY BEH C18 column at a flow rate of 0.70 ml/min. The average intra-assay coefficients of variation were 4.6% for PHE and 4.3% for tyrosine. The total coefficients of variation were 3.7% for PHE and 3.1% for tyrosine. Detection limits were 3.3 μM for PHE and 2.0 μM for tyrosine. The linear range was 25–500 μM.
Measurement of plasma p-cresyl sulfate and PHE-derived downstream metabolites
Plasma concentrations of p-cresyl sulfate (total form) and PHE-derived downstream metabolites were measured using UPLC tandem mass spectrometry on a Xevo TQ MS Acquity UPLC system (Waters). Details are provided in the supplemental materials.
Assessment of mortality
All-cause mortality was assessed over a 15-day follow-up period.
Statistical analysis
Results are expressed as mean ± SD values for continuous variables with a normal distribution, as medians and interquartile ranges for variables with a skewed distribution, and as numbers and percentages for categorical variables. Data were compared using an independent t test, the Mann–Whitney U test, the chi-square test, and the Spearmen correlation, as appropriate. To match patients in the UD and PFD groups, propensity scores were calculated using variables from Supplemental Table 2* that had a baseline p value of <0.1. Between-group comparisons of changes in laboratory parameters were performed using a two-factor, repeated-measures analysis of variance. All statistical analyses were two-sided and performed in SPSS (ver. 22.0; IBM Corp., Armonk, NY). A p value of <0.05 was considered to be significant.
Results
Baseline characteristics
As shown in Fig. 1, 731 potentially eligible patients were identified. Blood PHE levels were measured on Day 1. In total, 475 patients were excluded. Exclusions were applied for blood PHE level <95 μM, death on the first day, and discharge against advice. Ultimately, 256 patients were enrolled, 61 of whom agreed to receive a PFD and were allocated to the PFD group. The other 195 patients were allocated to the UD group. The dietary intervention lasted 5 days. During the intervention, 28 patients in the PFD group and 76 patients in the UD group were further excluded because of temporary hemodialysis, death, incomplete laboratory test data, feeding interruption, or refusal of blood collection on Day 5. The remaining 33 and 119 patients in the PFD and UD groups, respectively, were matched using propensity scores at a 1:1 ratio. Baseline characteristics are summarized in Supplemental Table 2*. Propensity scores (determined using age and plasma PHE levels at baseline) were used for matching.
PHE-derived metabolites and proinflammatory cytokines were analyzed in 33 patients from the PFD group and 33 matched patients from the UD group. Among these patients, 41 (62.1%) had been admitted to the ICU for heart failure due to coronary artery disease, myocardial infarction, or other heart failure etiologies, and 25 (37.9%) had been admitted for infection. The baseline characteristics of the matched UD and PFD groups are presented in Table 1. No significant between-group differences were noted in plasma PHE levels or clinicodemographic characteristics.
Table 1.
Demographic and laboratory data in the matched groups (n = 66)
| Usual diet group (n = 33) | PHE-free group (n = 33) | p value | |
|---|---|---|---|
| Age (years) | 76.1 ± 10.3 | 75.9 ± 10.9 | 0.918 |
| Male (%) | 19 (57.6) | 21 (63.6) | 0.614 |
| APACHE II score | 18.7 ± 5.12 | 19.1 ± 5.19 | 0.849 |
| SOFA score | 6.52 ± 2.24 | 7.15 ± 2.94 | 0.326 |
| Co-morbidity | |||
| Diabetes mellitus (%) | 13 (39.4) | 13 (39.4) | 1.000 |
| Hypertension (%) | 22 (66.7) | 18 (54.5) | 0.314 |
| Atrial fibrillation (%) | 7 (21.2) | 4 (12.1) | 0.322 |
| Ventilator use (%) | 29 (87.9) | 32 (97.0) | 0.163 |
| Inotropic agent use (%) | 10 (30.3) | 14 (42.4) | 0.306 |
| Laboratory data | |||
| WBC (1,000/μl) | 13.3 ± 7.3 | 12.6 ± 6.70 | 0.656 |
| Hemoglobin (g/dl) | 10.7 ± 2.64 | 11.0 ± 2.66 | 0.536 |
| CRP (mg/L) | 61.1 (18.7–114) | 80.1 (10.7–118) | 0.586 |
| Cholesterol (mg/dl) | 127 ± 45.9 | 121 ± 30.3 | 0.491 |
| Triglyceride (mg/dl) | 128 ± 57.3 | 139 ± 97.6 | 0.531 |
| Albumin (g/dl) | 3.18 ± 0.51 | 3.05 ± 0.67 | 0.382 |
| eGFR (ml/min/1.73 m2) | 44.5 ± 31.7 | 54.4 ± 29.0 | 0.188 |
| Phenylalanine (μM) | 125 ± 24.5 | 136 ± 44.7 | 0.173 |
Data are expressed as the mean ± SD for variables with normal distribution, median [interquartile range (IQR)] for variables with skewed distribution, and as number (percentage) for categorical variables. APACHE, acute physiology and chronic health evaluation; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; PHE, phenylalanine.
Dietary intake
Dietary intake was compared between the groups. No significant difference was noted in caloric intake (Table 2). Fat intake was lower in the PFD group than in the UD group, whereas protein intake and carbohydrate intake were similar between the two groups. The PFD group received less PHE, vitamin E, choline, and manganese but more tyrosine, vitamins (A, B12, D, and K), folic acid, thiamin, riboflavin, niacin, pantothenic acid, iron, zinc, copper, iodine, selenium, potassium, chloride, calcium, phosphorus, magnesium, and sodium than did the UD group. Both groups received similar amounts of vitamins C and B6, biotin, chromium, and molybdenum. After the intervention, patients were switched to a standard diet prescribed by dieticians on the basis of patient condition.
Table 2.
Comparison of the intake components between matched groups (n = 66)
| Usual diet group (n = 33) | PHE-free group (n = 33) | p value | |
|---|---|---|---|
| Weight (kg) | 61.2 ± 10.9 | 58.8 ± 11.7 | 0.434 |
| Body Mass Index (kg/m2) | 24.3 ± 3.76 | 22.9 ± 3.91 | 0.185 |
| Calories (kcal/day) | 1,144 ± 397 | 957 ± 341 | 0.076 |
| Protein (g/day) | 52.0 ± 18.4 | 57.4 ± 23.0 | 0.356 |
| Fat (g/day) | 52.2 ± 24.8 | 33.0 ± 14.1 | 0.003 |
| Carbohydrate (g/day) | 117 ± 55.7 | 100 ± 41.8 | 0.212 |
| Phenylalanine (mg/day) | 2,616 ± 915 | 547 ± 539 | <0.001 |
| Tyrosine (mg/day) | 2,471 ± 880 | 5,174 ± 2,228 | <0.001 |
| Vitamin A (μg RAE/day) | 768 ± 506 | 1,170 ± 590 | 0.012 |
| Vitamin D (μg/day) | 7.32 ± 4.35 | 31.0 ± 19.6 | <0.001 |
| Vitamin E (mg α-TE/day) | 26.2 ± 16.0 | 18.3 ± 7.32 | 0.040 |
| Vitamin K (μg/day) | 85.9 ± 36.1 | 112 ± 46.7 | 0.033 |
| Vitamin C (mg/day) | 140 ± 74.6 | 125 ± 47.8 | 0.371 |
| Folic acid (μg/day) | 434 ± 258 | 772 ± 304 | <0.001 |
| Thiamin (mg/day) | 1.97 ± 0.83 | 4.80 ± 2.76 | <0.001 |
| Riboflavin (mg/day) | 2.00 ± 0.81 | 2.79 ± 1.22 | 0.006 |
| Vitamin B6 (mg/day) | 2.94 ± 1.87 | 2.50 ± 0.88 | 0.307 |
| Vitamin B12 (μg/day) | 5.49 ± 3.31 | 8.09 ± 3.93 | 0.014 |
| Niacin (mg NE/day) | 24.4 ± 14.2 | 42.2 ± 16.6 | <0.001 |
| Choline (mg/day) | 421 ± 165 | 267 ± 103 | <0.001 |
| Biotin (μg/day) | 216 ± 205 | 177 ± 81.4 | 0.402 |
| Pantothenic acid (mg/day) | 10.0 ± 4.85 | 13.9 ± 6.01 | 0.015 |
| Iron (mg/day) | 12.7 ± 4.97 | 24.9 ± 9.78 | <0.001 |
| Zinc (mg/day) | 14.6 ± 6.28 | 25.0 ± 9.58 | <0.001 |
| Manganese (mg/day) | 3.09 ± 1.49 | 2.34 ± 1.00 | 0.031 |
| Copper (mg/day) | 1.41 ± 0.56 | 2.75 ± 1.11 | <0.001 |
| Iodine (μg/day) | 117 ± 43.0 | 176 ± 75.5 | 0.001 |
| Selenium (μg/day) | 53.9 ± 20.7 | 69.1 ± 25.9 | 0.026 |
| Chromium (μg/day) | 83.9 ± 36.4 | 70.8 ± 26.1 | 0.130 |
| Molybdenum (μg/day) | 90.4 ± 39.2 | 76.1 ± 28.9 | 0.129 |
| Potassium (mg/day) | 1,246 ± 563 | 2,478 ± 1042 | <0.001 |
| Chloride (mg/day) | 1,091 ± 517 | 1,802 ± 721 | <0.001 |
| Calcium (mg/day) | 729 ± 284 | 1,689 ± 721 | <0.001 |
| Phosphorus (mg/day) | 655 ± 260 | 1,437 ± 586 | <0.001 |
| Magnesium (mg/day) | 228 ± 103 | 399 ± 171 | <0.001 |
| Sodium (mg/day) | 730 ± 533 | 1,522 ± 662 | <0.001 |
RAE, retinol activity equivalent; α-TE, alpha-tocopherol; NE, niacin equivalent.
The changes in daily calorie, protein, and PHE intakes from Day 1 to Day 4 for both groups are presented in Table 3. On Day 1, baseline calorie and protein intakes were similar between the two groups. However, PHE intake was lower in the PFD group than in the UD group. From Day 1 to Day 4, the PFD group showed a significant increase in protein intake compared to the UD group (p = 0.045). Furthermore, PHE intake significantly decreased in the PFD group (p<0.001), whereas it remained unchanged in the UD group (p = 0.153).
Table 3.
Comparisons in the changes of calorie, protein, and phenylalanine (PHE) intake per day from the first day (Day 1) to the final day (Day 4) of diet intervention in the matched Usual diet and PHE-free diet groups
| Usual diet group (n = 33) | PHE-free diet group (n = 33) | p value† | p value‡ | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 4 | p value* | Day 1 | Day 4 | p value* | ||||
| Calorie (kcal/day) | 1,026 ± 498 | 1,076 ± 456 | 0.593 | 1,010 ± 497 | 931 ± 423 | 0.382 | 0.498 | 0.319 | |
| Protein (g/day) | 49.0 ± 21.2 | 54.5 ± 21.1 | 0.161 | 40.7 ± 22.7 | 59.7 ± 27.7 | 0.001 | 0.129 | 0.045 | |
| Phenylalanine (mg/day) | 2,525 ± 1,494 | 2,906 ± 1,367 | 0.153 | 1,858 ± 1,036 | 0 ± 0 | <0.001 | 0.039 | <0.001 | |
Data are presented as mean ± SD. *Comparison from Day 1 to Day 4 within the group; †Comparison between groups at baseline; ‡Comparison between groups in the change from baseline to Day 4 (by a two-factor repeated measurements analysis of variance).
Changes in PHE and PHE-derived metabolites
From baseline to Day 5, both matched groups exhibited significant reductions in plasma PHE level (from 136 ± 44.7 to 97.0 ± 41.7 μM in the PFD group, p<0.001; from 125 ± 24.5 to 108 ± 30.9 μM in the UD group, p<0.001; Table 4). However, this reduction was significantly greater in the PFD group than in the UD group (−39.9 ± 34.9 vs −16.5 ± 34.2 μM, respectively; p = 0.008). Factors associated with the postintervention reduction in PHE level were analyzed. Although the intake of many macronutrients and micronutrients differed significantly between the two groups, only PHE intake was significantly associated with the reduction in PHE level (Supplemental Table 3*).
Table 4.
Comparisons in the changes of phenylalanine (PHE) and phenylalanine-derived downstream metabolites from baseline to Day 5 in the matched Usual diet and PHE-free diet groups
| Usual diet group (n = 33) | PHE-free diet group (n = 33) | p value† | p value‡ | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Day 5 | Changes | p value* | Baseline | Day 5 | Changes | p value* | ||||
| Phenylalanine (μM) | 125 ± 24.5 | 108 ± 30.9 | −16.5 ± 34.2 | <0.001 | 136 ± 44.7 | 97.0 ± 41.7 | −39.9 ± 34.9 | <0.001 | 0.173 | 0.008# | |
| Tyrosine (μM) | 111 ± 53.1 | 87.4 ± 32.3 | −23.3 ± 44.1 | <0.001 | 101 ± 31.5 | 111 ± 40.5 | 9.27 ± 36.7 | <0.001 | 0.384 | 0.002# | |
| P-cresyl sulfate (μM) | 84.5 ± 22.4 | 46.3 ± 17.1 | −38.1 ± 32.2 | <0.001 | 85.9 ± 18.4 | 41.4 ± 6.6 | −44.5 ± 18.7 | <0.001 | 0.792 | 0.343 | |
| Phenylacetate (μM) | 4.19 ± 1.33 | 2.66 ± 1.04 | −1.53 ± 1.44 | <0.001 | 4.81 ± 1.46 | 2.59 ± 0.99 | −2.22 ± 1.00 | <0.001 | 0.312 | 0.088 | |
| Phenylpyruvate (μM) | 19.4 ± 8.8 | 12.8 ± 4.1 | −6.12 ± 8.76 | <0.001 | 21.9 ± 11.2 | 11.3 ± 2.7 | −11.12 ± 9.43 | <0.001 | 0.632 | 0.038# | |
| Phenyllactate (μM) | 26.8 ± 10.0 | 16.5 ± 5.65 | −10.3 ± 10.6 | <0.001 | 33.1 ± 11.4 | 17.4 ± 4.84 | −15.7 ± 9.11 | <0.001 | 0.114 | 0.127 | |
| OH-phenylacetate (μM) | 2.63 ± 0.66 | 2.19 ± 0.45 | −0.43 ± 0.67 | 0.001 | 2.85 ± 0.62 | 2.05 ± 0.41 | −0.83 ± 0.66 | <0.001 | 0.312 | 0.176 | |
| OH-phenylpyruvate (μM) | 2.73 ± 0.78 | 1.75 ± 0.36 | −0.99 ± 0.90 | <0.001 | 3.18 ± 0.88 | 1.74 ± 0.38 | −1.43 ± 0.74 | <0.001 | 0.142 | 0.127 | |
| OH-phenyllactate (μM) | 2.10 ± 0.64 | 1.02 ± 0.41 | −1.08 ± 0.70 | <0.001 | 2.47 ± 0.65 | 1.02 ± 0.34 | −1.44 ± 0.45 | <0.001 | 0.132 | 0.017# | |
Data are presented as mean ± SD. *Comparison from baseline to Day 5 within the group; †Comparison between groups at baseline; ‡Comparison between groups in the change from baseline to Day 5 (by a two-factor repeated measurements analysis of variance); #p<0.05. OH-, hydroxyl-.
Tyrosine level significantly decreased in the UD group (from 111 ± 53.1 to 87.4 ± 32.3 μM, p<0.001) but increased in the PFD group (from 101 ± 31.5 to 111 ± 40.5 μM, p<0.001). The mean change in tyrosine level was significantly higher in the PFD group than in the UD group (9.27 ± 36.7 vs −23.3 ± 44.1 μM, respectively; p = 0.002). The level of p-cresyl sulfate (a toxic metabolite of tyrosine produced by the gut flora) decreased similarly in both groups.
Baseline and postintervention levels of PHE-derived downstream metabolites in each group are listed in Table 4; no significant between-group differences were observed in baseline levels. The PFD group exhibited significantly greater reductions in phenylpyruvate and hydroxyl-phenyllactate levels than did the UD group (both p<0.05). No significant differences were noted in other downstream metabolites.
Changes in proinflammatory cytokines
Data pertaining to proinflammatory cytokines are presented in Fig. 2, with details in Supplemental Table 4*. At baseline, no significant between-group differences were observed in cytokine levels. The PFD group exhibited significantly greater reductions in levels of IL-6 (p = 0.026), IL-10 (p = 0.020), tumor necrosis factor-α (p = 0.009), and macrophage inflammatory protein-1β (p = 0.006) and a smaller increase in ITAC level (p = 0.013) than did the UD group. No significant differences were noted in other cytokines.
Fig. 2.

Changes in proinflammatory cytokines. Box-and-Whisker plots are shown. †p<0.05, comparisons between groups in the changes from baseline to Day 5 by a two-factor repeated measurements analysis of variance. IL, interleukin; ITAC, interferon-inducible T-cell α chemoattractant; MIP, macrophage inflammatory protein; NS, non-significant; TNF, tumor necrosis factor.
Factors associated with reductions in proinflammatory cytokine levels
As shown in Supplemental Table 5*, lower PHE intake during the intervention was associated with greater reductions in IL-6, tumor necrosis factor-α, macrophage inflammatory protein-1, and ITAC levels. Reductions in plasma PHE level were positively correlated with reductions in IL-10 level. Greater tyrosine intake was correlated with greater reductions in macrophage inflammatory protein-1β and ITAC levels. Higher levels of vitamins D and B1, folic acid, iron, zinc, copper, potassium, chloride, calcium, phosphate, and magnesium intake were associated with greater reductions in ITAC level. Next, we aimed to identify the factors independently associated with the changes in cytokines. However, due to severe multicollinearity among the factors (with variance inflation factors ranging from 9.2 to 55.3), multivariable analysis was not conducted. Our current data suggest that the amount of PHE intake plays a significant role in reducing proinflammatory cytokine levels. Specifically, a lower PHE intake exhibited the highest statistical significance (lowest p value) in its correlation with greater reductions in IL-6, tumor necrosis factor-α, macrophage inflammatory protein-1, and ITAC levels (Supplemental Table 5*). In addition, the reduction in plasma PHE levels from baseline to Day 5 was the only factor independently associated with decreased IL-10 levels.
Mortality
The PFD group was associated with a trend of lower 15-day mortality rate, compared to the UD group [2 deaths (6.1%) vs 7 deaths (21.2%), p = 0.072].
Discussion
Caloric intake was similar between the UD and PFD groups. The PFD was enriched with PHE-free protein and antioxidant micronutrients. PFD intake markedly reduced the plasma levels of PHE, PHE-derived downstream metabolites, and proinflammatory cytokines in ICU patients with HPA. A lower intake of PHE and a greater intake of micronutrients were associated with lower levels of proinflammatory cytokines. Furthermore, PFD intake was associated with a trend of lower 15-day mortality rate. Additional investigations are required to determine whether the observed associations are causal.
Studies have demonstrated a linear correlation between plasma PHE level and mortality risk.(5,9–12) Data indicate that for every 10-μM increase in plasma PHE level above the normal limit of 85 μM, the risk of mortality increases by 8.7%.(12) In patients with heart failure or a critical illness, elevated plasma PHE level has been associated with increased tissue efflux due to poor perfusion–related breakdown(12,24,25) and impaired metabolism due to liver congestion, shock liver, or kidney dysfunction.(3,5,24,25) Systemic inflammation and oxidative stress impair PAH function by depleting tetrahydrobiopterin, an antioxidant and essential PAH cofactor.(3,5,12,24) These mechanisms differ fundamentally from those in patients with congenital PKU, where HPA results from PAH mutations and inhibits PHE release from tissues.(13) Although PHE restriction is the established treatment for PKU,(14) the distinct mechanisms underlying HPA in patients without PKU warrant further investigation into the effects of a PFD in this population.
PFDs limit the dietary intake of PHE but cannot directly attenuate tissue breakdown or improve liver or kidney function. Nevertheless, our study revealed that a PFD effectively reduced plasma PHE levels. Other studies have associated higher plasma PHE levels with higher proinflammatory cytokine levels.(5,9) The PFD in our study reduced not only the plasma level of PHE but also the plasma levels of many crucial proinflammatory cytokines. Consistent with these findings, an in vitro study reported that accumulated PHE exerts detrimental effects by inducing the production of mitochondrial reactive oxygen species and then activating the inflammasome and caspase-1, leading to endothelial secretion of IL-1β and IL-18 and subsequent pyroptosis.(26) In an animal model of stroke, a PHE-restricted diet reduced PHE levels and attenuated inflammation. Further studies are required to confirm a definitive causal relationship.
We previously demonstrated that elevated plasma PHE levels indicate a disruption in PHE catabolism due to overloaded alternative pathways, resulting in the overproduction of toxic metabolites such as phenylpyruvate, phenyallactate, and phenylacetate,(27) which promote oxidative stress and inflammation.(28–30) The PFD in the present study signficantly reduced the plasma levels of phenylpyriuvate and PHE. Consistent with these findings, another study demonstrated that excess phenylpyruvate is internalized by macrophages through the scavenger receptor CD36, increasing NLRP3 protein palmitoylation and promoting inflammasome activation and inflammatory factor (e.g., IL-1β) release.(20) In a mouse model of chronic wound, a PHE-restricted diet reduced phenylpyruvate accumulation in wounds, attenuated excessive inflammation, and promoted healing. Neuroscience research suggests that high PHE levels reduce pyruvate kinase activity and impair mitochondrial pyruvate uptake, leading to defective tricarboxylic acid cycle function and impaired adenosine triphosphate synthesis.(31,32)
Intriguingly, a reduction in blood PHE levels was also observed in the UD group, despite their daily PHE intake remaining constant throughout the intervention period. This finding could be attributed to several factors. First, the cumulative PHE intake over the entire 5-day intervention period may have influenced the observed changes; based on daily caloric calculations, the daily PHE intake of patients in the UD group (~1,144 kcal/day) was likely lower than the expected intake for individuals without critical illness. On the other hand, as aforementioned, blood PHE levels are closely associated with tissue perfusion,(12,24,25) liver and kidney function,(3,5,24,25) inflammation, and oxidative stress.(3,5,12,24) Consequently, improvements in these aspects in response to treatment from baseline to Day 5 may be related to the reduction in PHE levels within the UD group as well.
Studies have associated increased plasma antioxidant micronutrient levels with greater glutathione peroxidase activity in patients with PKU.(33–35) Our data suggest that the anti-inflammatory effects of PFDs are partially related to increased dietary micronutrient content; specifically, higher intake of vitamins D and B1, folic acid, iron, zinc, and copper was associated with a greater reduction in ITAC level. Vitamins D and B1, folic acid, zinc, and copper are well-documented for their anti-inflammatory properties.(36–38) Several studies have supported the efficacy of antioxidant micronutrients in alleviating inflammation in critically ill patients.(39–41) Attenuation of inflammation and oxidative stress may provide positive feedback that improves PHE metabolism and reduces PHE levels. High-fat diets are considered proinflammatory because their metabolites serve as precursors for inflammatory mediators.(42) Thus, the reduced fat intake in the PFD group might have contributed to the reductions in proinflammatory cytokines.
Commercial PFDs are enriched with tyrosine (Supplemental Table 1*) because tyrosine production is impaired in individuals for whom these diets are typically formulated (i.e., patients with PKU). However, tyrosine production is not impaired in patients with non-PKU-related HPA. In our study, tyrosine levels were elevated and further increased after the administration of the PFD without a corresponding increase in the level of p-cresyl sulfate—a nephrotoxic metabolite of PHE and tyrosine. A greater intake of tyrosine was associated with lower levels of ITAC and macrophage inflammatory protein-1β. The anti-inflammatory effect of tyrosine was demonstrated also by Uehara et al.(43) The presence and number of hydroxyl groups in the side chains of tyrosine-derived metabolites negatively influence the production of reactive oxygen species in the mitochondria.(30) However, Zhao et al. associated increased plasma tyrosine levels with cardiomyocyte apoptosis and heart failure.(44) Accordingly, the overall health benefit of tyrosine supplementation requires further study for clarification.
Limitations
This study has some limitations. First, although a PFD that is beneficial for patients with PKU is likely beneficial also for patients with HPA, the diet’s critical components are not fully explored. Second, this study was not a randomized clinical trial. Despite successful propensity score matching to balance the groups in terms of baseline characteristics, our results are not immune to selection bias. Propensity score matching only accounts for observed variables included in the model; residual confounding due to unmeasured or unobserved factors may persist. The clinical benefits of PFDs should be investigated in studies with larger sample sizes and longer intervention durations. Finally, blood PHE levels may not completely reflect PHE variations in response to the PFD, as a substantial amount of PHE and its downstream metabolites can be excreted by the kidneys. Measuring urinary excretion of PHE and downstream metabolites, in addition to blood quantification, may provide additional insights into the effects of PFD. Future studies are needed to clarify the value of urinary measurement during PFD intervention.
Conclusion
Our study revealed that the intake of a PHE-lowering diet containing abundant PHE-free protein and antioxidant micronutrients reduced the plasma levels of PHE and proinflammatory cytokines in critically ill patients with HPA. Randomized placebo-controlled trials are warranted to confirm the benefits of this diet.
Author Contributions
WSC, MHL, and YTL contributed to writing—original draft preparation. WSC, MHL, CHW, YTL, YPP, HYC, and JYL contributed to conceptualization, and methodology. CMC, HPW, and YLT were involved in formal analysis and investigation. YTL, YPP, HYC, and JYL were involved in investigation. MHL, CHW, and WTH contributed to writing—review and editing. WSC and CHW were involved in resources and funding acquisition. WSC and WTH contributed to supervision. All authors contributed to the conduction of the study and reviewed and approved the final version of the manuscript.
Funding
This study was supported in part by the Ministry of Science and Technology of Taiwan (MOST109-2314-B-182-056-MY3; NSTC114-2321-B-182-006), and Chang Gung Memorial Hospital (CMRPG2L0141; CPRPG2M0011; CPRPG2L0141; CMRPG2P0201).
Acknowledgments
The authors would like to thank the Intensive Care Unit of the Chang Gung Memorial Hospital, Keelung, for software, instrument availability, and assistance. This manuscript was edited by Wallace Academic Editing.
Conflict of Interest
No potential conflicts of interest were disclosed.
Supplementary Material
References
- 1.Chandel A, Leazer S, Alcover KC, et al. Intensive care and organ support related mortality in patients with COVID-19: a systematic review and meta-analysis. Crit Care Explor 2023; 5: e0876. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Maslove DM, Tang B, Shankar-Hari M, et al. Redefining critical illness. Nat Med 2022; 28: 1141–1148. [DOI] [PubMed] [Google Scholar]
- 3.Delles C, Rankin NJ, Boachie C, et al. Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997. Eur J Heart Fail 2018; 20: 663–673. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Würtz P, Havulinna AS, Soininen P, et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 2015; 131: 774–785. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Chen WS, Wang CH, Cheng CW, et al. Elevated plasma phenylalanine predicts mortality in critical patients with heart failure. ESC Heart Fail 2020; 7: 2884–2893. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Buchmueller LC, Wunderle C, Laager R, et al. Association of phenylalanine and tyrosine metabolism with mortality and response to nutritional support among patients at nutritional risk: a secondary analysis of the randomized clinical trial EFFORT. Front Nutr 2024; 11: 1451081. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Neurauter G, Schröcksnadel K, Scholl-Bürgi S, et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab 2008; 9: 622–627. [DOI] [PubMed] [Google Scholar]
- 8.Oh AR, Ryu JA, Lee SJ, Kim CS, Lee SM. Association between inflammation-based prognostic markers and mortality in patients admitted to intensive care units. Diagnostics (Basel) 2024; 14: 1709. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Huang SS, Lin JY, Chen WS, et al. Phenylalanine- and leucine-defined metabolic types identify high mortality risk in patients with severe infection. Int J Infect Dis 2019; 85: 143–149. [DOI] [PubMed] [Google Scholar]
- 10.Luporini RL, Pott-Junior H, Di Medeiros Leal MCB, et al. Phenylalanine and COVID-19: tracking disease severity markers. Int Immunopharmacol 2021; 101 (Pt A): 108313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Atila A, Alay H, Yaman ME, et al. The serum amino acid profile in COVID-19. Amino Acids 2021; 53: 1569–1588. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Wang CH, Chen WS, Liu MH, et al. Stress hyperphenylalaninemia is associated with mortality in cardiac ICU: clinical factors, genetic variants, and pteridines. Crit Care Med 2022; 50: 1577–1587. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Hillert A, Anikster Y, Belanger-Quintana A, et al. The genetic landscape and epidemiology of phenylketonuria. Am J Hum Genet 2020; 107: 234–250. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Romani C, Manti F, Nardecchia F, et al. Adult cognitive outcomes in phenylketonuria: explaining causes of variability beyond average Phe levels. Orphanet J Rare Dis 2019; 14: 273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Czibik G, Mezdari Z, Murat Altintas D, et al. Dysregulated phenylalanine catabolism plays a key role in the trajectory of cardiac aging. Circulation 2021; 144: 559–574. [DOI] [PubMed] [Google Scholar]
- 16.Xu J, Pan T, Qi X, et al. Increased mortality of acute respiratory distress syndrome was associated with high levels of plasma phenylalanine. Respir Res 2020; 21: 99. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Ubhi BK, Riley JH, Shaw PA, et al. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J 2012; 40: 345–355. [DOI] [PubMed] [Google Scholar]
- 18.Tan R, Li J, Liu F, et al. Phenylalanine induces pulmonary hypertension through calcium-sensing receptor activation. Am J Physiol Lung Cell Mol Physiol 2020; 319: L1010–L1020. [DOI] [PubMed] [Google Scholar]
- 19.Aquilani R, La Rovere MT, Febo O, et al. Lung anabolic activity in patients with chronic heart failure: potential implications for clinical practice. Nutrition 2012; 28: 1002–1007. [DOI] [PubMed] [Google Scholar]
- 20.Lv D, Cao X, Zhong L, et al. Targeting phenylpyruvate restrains excessive NLRP3 inflammasome activation and pathological inflammation in diabetic wound healing. Cell Rep Med 2023; 4: 101129. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Mazzola PN, Karikas GA, Schulpis KH, Dutra-Filho CS. Antioxidant treatment strategies for hyperphenylalaninemia. Metab Brain Dis 2013; 28: 541–550. [DOI] [PubMed] [Google Scholar]
- 22.McClave SA, Martindale RG, Vanek VW, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009; 33: 277–316. [DOI] [PubMed] [Google Scholar]
- 23.Weimann A, Braga M, Carli F, et al. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr 2017; 36: 623–650. [DOI] [PubMed] [Google Scholar]
- 24.Cheng CW, Liu MH, Tang HY, Cheng ML, Wang CH. Factors associated with elevated plasma phenylalanine in patients with heart failure. Amino Acids 2021; 53: 149–157. [DOI] [PubMed] [Google Scholar]
- 25.Gore DC, Wolfe RR, Chinkes DL. Quantification of amino acid transport through interstitial fluid: assessment of four-compartment modeling for muscle protein kinetics. Am J Physiol Endocrinol Metab 2007; 292: E319–E323. [DOI] [PubMed] [Google Scholar]
- 26.Wang Y, Guan X, Gao CL, et al. Medioresinol as a novel PGC-1α activator prevents pyroptosis of endothelial cells in ischemic stroke through PPARα-GOT1 axis. Pharmacol Res 2021; 169: 105640. [DOI] [PubMed] [Google Scholar]
- 27.Chen WS, Liu MH, Tsou YL, et al. Extensive dysregulation of phenylalanine metabolism is associated with stress hyperphenylalaninemia and 30-day death in critically ill patients with acute decompensated heart failure. J Am Heart Assoc 2024; 13: e035821. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Hadjiconstantinou M, Neff NH. Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson’s disease. CNS Neurosci Ther 2008; 14: 340–351. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochem Rev 2008; 29: 31–41. [PMC free article] [PubMed] [Google Scholar]
- 30.Fedotcheva NI, Kazakov RE, Kondrashova MN, Beloborodova NV. Toxic effects of microbial phenolic acids on the functions of mitochondria. Toxicol Lett 2008; 180: 182–188. [DOI] [PubMed] [Google Scholar]
- 31.Schell JC, Rutter J. The long and winding road to the mitochondrial pyruvate carrier. Cancer Metab 2013; 1: 6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Weber G. Inhibition of human brain pyruvate kinase and hexokinase by phenylalanine and phenylpyruvate: possible relevance to phenylketonuric brain damage. Proc Natl Acad Sci U S A 1969; 63: 1365–1369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Lombeck I, Jochum F, Terwolbeck K. Selenium status in infants and children with phenylketonuria and in maternal phenylketonuria. Eur J Pediatr 1996; 155 (Suppl 1): S140–S144. [DOI] [PubMed] [Google Scholar]
- 34.Sitta A, Barschak AG, Deon M, et al. Effect of short- and long-term exposition to high phenylalanine blood levels on oxidative damage in phenylketonuric patients. Int J Dev Neurosci 2009; 27: 243–247. [DOI] [PubMed] [Google Scholar]
- 35.Wilke BC, Vidailhet M, Favier A, et al. Selenium, glutathione peroxidase (GSH-Px) and lipid peroxidation products before and after selenium supplementation. Clin Chim Acta 1992; 207: 137–142. [DOI] [PubMed] [Google Scholar]
- 36.Song M, Xu BP. The anti-inflammatory effects of folic acid. Precis Nutr 2024; 3: e00070. [Google Scholar]
- 37.Zaringhalam J, Akbari A, Zali A, et al. Long-term treatment by vitamin B1 and reduction of serum proinflammatory cytokines, hyperalgesia, and paw edema in adjuvant-induced arthritis. Basic Clin Neurosci 2016; 7: 331–340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Napiórkowska-Baran K, Treichel P, Dardzińska A, et al. Immunomodulatory effects of selected non-nutritive bioactive compounds and their role in optimal nutrition. Curr Issues Mol Biol 2025; 47: 89. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Berger MM, Soguel L, Shenkin A, et al. Influence of early antioxidant supplements on clinical evolution and organ function in critically ill cardiac surgery, major trauma, and subarachnoid hemorrhage patients. Crit Care 2008; 12: R101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Koekkoek WAC, Hettinga K, de Vries JHM, van Zanten ARH. Micronutrient deficiencies in critical illness. Clin Nutr 2021; 40: 3780–3786. [DOI] [PubMed] [Google Scholar]
- 41.Notz Q, Herrmann J, Schlesinger T, et al. Clinical significance of micronutrient supplementation in critically ill COVID-19 patients with severe ARDS. Nutrients 2021; 13: 2113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Duan Y, Zeng L, Zheng C, et al. Inflammatory links between high fat diets and diseases, Front Immunol 2018; 9: 2649. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Uehara A, Maekawa M, Nakagawa K. L-Tyrosine enhances tight junction integrity and anti-inflammatory properties: a potential alternative to antibiotic growth promoters in broilers. Arch Microbiol 2025; 207: 329. [DOI] [PubMed] [Google Scholar]
- 44.Zhao R, Cai K, Yang JJ, et al. Nuclear ATR lysine-tyrosylation protects against heart failure by activating DNA damage response. Cell Rep 2023; 42: 112400. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
